ICD Primary prevention trials: Difference between revisions

Jump to navigation Jump to search
no edit summary
No edit summary
No edit summary
Line 12: Line 12:
! Main Finding
! Main Finding
|-
|-
| MADIT I<sup>35</sup>
| MADIT I<cite>35</cite>
| Prior MI, EF ≤35%, NSVT, inducible and nonsuppressible VT on EPS, NYHA class I–III
| Prior MI, EF ≤35%, NSVT, inducible and nonsuppressible VT on EPS, NYHA class I–III
| align="center" | 196
| align="center" | 196
Line 20: Line 20:
mortality with ICD (''P''=0.009); absolute RR 23%
mortality with ICD (''P''=0.009); absolute RR 23%
|-
|-
| CABG-PATCH<sup>36</sup>
| CABG-PATCH<cite>36</cite>
| EF <35%, abnormal SAECG, elective CABG
| EF <35%, abnormal SAECG, elective CABG
| align="center" | 900
| align="center" | 900
Line 28: Line 28:


|-
|-
| MUSTT<sup>37</sup>
| MUSTT<cite>37</cite>
| Prior MI, EF ≤40%, NSVT, inducible VT on EPS
| Prior MI, EF ≤40%, NSVT, inducible VT on EPS
| align="center" | 704  
| align="center" | 704  
Line 36: Line 36:


|-
|-
| MADIT II<sup>39</sup>
| MADIT II<cite>39</cite>
| Prior MI≤1 month, EF≤30%, NYHA class I–III
| Prior MI≤1 month, EF≤30%, NYHA class I–III
| align="center" | 1232
| align="center" | 1232
Line 44: Line 44:


|-
|-
| DINAMIT<sup>38</sup>
| DINAMIT<cite>38</cite>
| Recent (6–40 days) MI, EF≤35%, abnormal HRV or elevated average HR on 24-h Holter, NYHA class I–III
| Recent (6–40 days) MI, EF≤35%, abnormal HRV or elevated average HR on 24-h Holter, NYHA class I–III
| align="center" | 674
| align="center" | 674
Line 52: Line 52:


|-
|-
| SCD-HeFT<sup>34</sup>
| SCD-HeFT<cite>34</cite>
| EF≤35%, (ischemic or nonischemic) NYHA class II–III
| EF≤35%, (ischemic or nonischemic) NYHA class II–III
| align="center" | 2521
| align="center" | 2521
Line 63: Line 63:


|}
|}
==References==
<biblio>
#34 Bardy G, Lee KL, Mark D, Poole J, Packer D, Boineau R, Domanski M, Troutman R, Anderson J, Johnson G, McNulty S, Clapp-Channing N, Davidson-Ray L, Fraulo E, Fishbein D, Luceri R, Ip J. Amiodarone or an implantable cardioverter- defibrillator for congestive heart failure. ''N Engl J Med.'' 2005;352:225–237.
#35 Moss A, Hall W, Cannom D, Daubert J, Higgins S, Klein H, Levine J, Saksena S, Waldo A, Wilber D, Brown M, Heo M; Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. ''N Engl J Med.'' 1996;335:1933–1940.
#36 Bigger J; Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. ''N Engl J Med.'' 1997;337:1569 –1575.
#37 Buxton A, Lee K, DiCarlo L, Gold M, Greer G, Prystowsky E, O’Toole M, Tang A, Fisher J, Coromilas J, Talajic M, Hafley G; Multicenter Unsustained Tachycardia Trial Investigators. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. ''N Engl J Med.'' 2000;342:1937–1945.
#38 Hohnloser S, Kuck KH, Dorian P, Roberts R, Hampton J, Hatala R, Fain E, Gent M, Connolly S; DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. ''N Engl J Med.'' 2004;351:2481–2488.
#39 Moss A, Zareba W, Hall W, Klein H, Wilber D, Cannom D, Daubert J, Higgins S, Brown M, Andrews M; for the MADIT II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. ''N Engl J Med.'' 2002;346:877–883.
</biblio>
81

edits

Navigation menu